|
Collaboration Arrangements - Additional Information (Detail) (Merck KGaA, USD $)
In Millions, unless otherwise specified |
3 Months Ended | |
|---|---|---|
|
Mar. 31, 2015
|
Mar. 31, 2014
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
| Upfront and milestone payments received to date | $ 110us-gaap_ProceedsFromCollaborators | |
| Merck KGaA's percentage share of worldwide development expenses | 70.00%thld_WorldwideDevelopmentExpensesSharePercentage | |
| Revenue recognized by the Company | 3.7us-gaap_DeferredRevenueRevenueRecognized | 3.7us-gaap_DeferredRevenueRevenueRecognized |
| Company received a reimbursement for eligible worldwide development expenses | 2.0us-gaap_RecoveryOfDirectCosts | 5.9us-gaap_RecoveryOfDirectCosts |
|
United States
|
||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
| Portion of profits that Company is eligible to participate, depending upon total sales |
50.00%thld_PortionOfProfitsDependingOnSales / dei_LegalEntityAxis = thld_MerckKGaAMember / us-gaap_StatementGeographicalAxis = country_US |
|
|
Regulatory and Development Milestones | Maximum
|
||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
| Potential future milestones |
100thld_PotentialMilestonePayments / dei_LegalEntityAxis = thld_MerckKGaAMember / us-gaap_RangeAxis = us-gaap_MaximumMember / thld_RequirementOfEligibleFutureMilestonePaymentsAxis = thld_RegulatoryAndDevelopmentMilestonesMember |
|
|
Commercialization Milestones | Maximum
|
||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
| Potential future milestones |
$ 340thld_PotentialMilestonePayments / dei_LegalEntityAxis = thld_MerckKGaAMember / us-gaap_RangeAxis = us-gaap_MaximumMember / thld_RequirementOfEligibleFutureMilestonePaymentsAxis = thld_CommercializationMilestonesMember |
|
| X | ||||||||||
|
- Definition
Portion of profits that Company is eligible to participate, depending upon total sales. No definition available.
|
| X | ||||||||||
|
- Definition
Potential future milestone payments. No definition available.
|
| X | ||||||||||
|
- Definition
Merck KGaA's percentage share of worldwide development expenses. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Cash received from collaborators during the current period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|